ABBV-951

ABBV-951 is subcutaneous delivery of Levodopa/Carbidopa being investigated for the treatment of Parkinson’s disease.

Type of Molecule

Small Molecule

Target

Dopamine Receptor

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Parkinson's Disease n/a
Phase 1